For immediate release
A NEW HOME-USE DEVICE TO HELP MONITOR LUNG FUNCTION AND COVID-19 CASES
Montreal, May 12th,2020 – Thorasys is pleased to announce the signature of a worldwide exclusive licensing agreement for the acquisition of REOM technology from Spiro-tech Inc. With the arrival of the COVID-19 pandemic, the need for an easy to use self-monitoring respiratory assessment tool has become apparent more than ever. Thorasys conducted an initial study in the fall of 2019 at the Ste Justine Hospital to evaluate the technology and after a positive outcome, the product development process is now moving forward at an accelerated pace to obtain formal approval as a medical device by the authorities.
“It has been demonstrated in many studies that home monitoring of lung health could prevent exacerbations and significantly reduce cost to the healthcare system and at the same time helping patients to control their disease and have a better quality of life. In the case of a pandemic such as COVID-19 having a simple device that can monitor patient lung health remotely is a fantastic asset and could help managing the flow of patients to the emergency unit”, declares Thomas Schuessler PhD, founder of Thorasys.
Dr. Chung-Wai Chow MD, PhD, FRCPC an Associate Professor at the University of Toronto has the same standpoint: “the introduction of a portable device for self-monitoring is a major innovative feature […] to help in the home management of COVID-19 patients worldwide. Monitoring patients with REOM will not only help in management of COVID-19 patients but will also have a wider impact and application for patients with chronic lung diseases. Knowing early who will develop severe disease will also help communities anticipate and better prepare health care resource allocation, thus facilitating early triage and management strategies to improve outcomes.”
REOM is a new technology to remotely monitor lung function via a pocket-size device and mobile app. Unlike other techniques that require patient effort, measurements are obtained during regular quiet breathing. It’s subject to two recent patent applications and has been tested in both the lab and in clinical pilot studies.
Thorasys is a small medium-sized enterprise (SME), based in Montreal, Quebec, Canada, which designs, manufactures and markets respiratory medical devices such as the tremoflo and the REOM®. Thorasys applies state-of-the-art research and technology in the development of products for the assessment and monitoring of lung diseases such as asthma, COPD and cystic fibrosis.